(a)

	n	Median	*P*-value
SD/PD	7	131 days	
PR	4	202 days	0.39

HR 0.49 (95% CI 0.095-2.54)

Progression-free Survival (%)

Survival time (days)

(b)

	n	Median	*P*-value
SD/PD	24	93 days	
PR	9	156 days	0.45

HR 0.74 (95% CI 0.33-1.62)

Progression-free Survival (%)

Survival time (days)

HR, hazard ratio;CI, confidence interval;PR, partial response;SD, stable disease;
PD, progressive disease.

Izawa et al. Supplemental Figure 2

(a)

	Correlation Coefficient	*P*-value
▲ TAX arm	0.084	0.21
○ RAM arm	0.41	0.21

(b)

	Correlation Coefficient	*P*-value
▲ TAX arm	0.084	0.64
○ RAM arm	0.072	0.83

(a)

		n	Median	*P*-value
——	ΔCT_{low}	6	293 days	0.98
—·—·—	ΔCT_{high}	5	409 days	

HR 0.98 (95% CI 0.21-4.42)

(b)

|		n	Median	*P*-value
——	ΔCT_{low}	17	283 days	0.47
—·—·—	ΔCT_{high}	16	276 days	

HR 1.30 (95% CI 0.62-2.74)

HR, hazard ratio;CI, confidence interval.

Izawa et al. Supplemental Figure 4

Supplemental Figure Legends:

Supplemental Figure 1. PFS estimated by RECIST version 1.1. A comparison of PFS (a) between patients showing PR and those showing SD/PD in the RAM arm. Similarly, a comparison of PFS (b) between patients showing PR and those with SD/PD in the TAX arm.

PFS, progression-free survival; PR, partial response; SD, stable disease; PD, progressive disease

Supplemental Figure 2. Scatter plot of CT value change and PFS (a), OS (b).

PFS, progression-free survival; OS, overall survival.

Supplemental Figure 3. OS estimated by CT value change. A comparison of OS (a) between patients showing high (ΔCThigh) and low rates of CT value change (ΔCTlow) in the RAM arm. Similarly, a comparison of OS (b) between patients showing ΔCThigh and ΔCTlow in the TAX arm.

PFS, progression-free survival; OS, overall survival.

Supplemental Figure 4. Scatter plot of CT value change and tumor size change.